EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

miR-137: A therapeutic candidate or a key molecular regulator in Alzheimer's disease?

Muhammad Wasim iD, Junhao Guo iD, Zhendong Wang iD, Rabia Parveen iD, Riling Chen, Yajun Wang iD, Guoda Ma iD

Journal of Alzheimer's Disease Reports · 2025-12 · 9

DOI: 10.1177/25424823251352166 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Alzheimer's Disease Reports, online erschienen am 25.06.2025. Verfasst von Muhammad Wasim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Maternal and Children's Health Research Institute, Shunde Women and Children's Hospital, Guangdong Medical University, Foshan, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 140 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, NSAF Joint Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) is a neurodegenerative disorder driven by amyloid-β accumulation, tau pathology, and synaptic dysfunction. Recent studies highlight miR-137, a brain-enriched microRNA, as a pivotal regulator of AD pathogenesis. This review synthesizes evidence that miR-137 modulates amyloid-β production, tau phosphorylation, synaptic plasticity, and neuroinflammation, while also preserving mitochondrial function and mitigating oxidative stress. Notably, circulating miR-137 levels correlate with AD progression, offering promise as a non-invasive diagnostic biomarker. Beyond diagnostics, miR-137's ability to target multiple AD-related pathways positions it as a novel therapeutic candidate for neuroprotection. Hence, miR-137 serves as both a biomarker and therapeutic target, offering promising strategies to slow AD progression and improve outcomes. Our bioinformatic analyses further identify miR-137-regulated genes and disrupted networks, underscoring its central role in AD. By bridging molecular mechanisms and clinical potential, miR-137-based strategies could transform AD management, addressing both pathological hallmarks and cognitive decline. Hence, this review article consolidates evidence of miR-137's multifaceted functions in AD, encouraging further investigation into its molecular mechanisms and translational potential to address this pathogenic condition.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer's diseasebiomarkermiR-137targettreatment

Autor:innen und Institutionen

  • Maternal and Children's Health Research Institute, Shunde Women and Children's Hospital, Guangdong Medical University, Foshan, China.
  • Institute of Pediatric, Shunde Women and Children Hospital, Guangdong Medical University, Foshan, China.
  • Department of Pediatrics, Shunde Women and Children Hospital, Guangdong Medical University, Foshan, China.

ORCID-Profile: Muhammad Wasim, Junhao Guo, Zhendong Wang, Rabia Parveen, Yajun Wang, Guoda Ma

Förderung

  • Basic and Applied Basic Research Foundation of Guangdong Province
  • NSAF Joint Fund

Zitieren

APA

Wasim, M., Guo, J., Wang, Z., Parveen, R., Chen, R., Wang, Y., & Ma, G. (2025). miR-137: A therapeutic candidate or a key molecular regulator in Alzheimer's disease?. Journal of Alzheimer's Disease Reports, 9. https://doi.org/10.1177/25424823251352166

Vancouver

Wasim M, Guo J, Wang Z, Parveen R, Chen R, Wang Y, et al. miR-137: A therapeutic candidate or a key molecular regulator in Alzheimer's disease?. Journal of Alzheimer's Disease Reports. 2025;9. doi:10.1177/25424823251352166

BibTeX
@article{Wasim2025,
  author = {Wasim, Muhammad and Guo, Junhao and Wang, Zhendong and Parveen, Rabia and Chen, Riling and Wang, Yajun and Ma, Guoda},
  title = {miR-137: A therapeutic candidate or a key molecular regulator in Alzheimer's disease?},
  journal = {Journal of Alzheimer's Disease Reports},
  year = {2025},
  volume = {9},
  doi = {10.1177/25424823251352166}
}
Kostenlos starten →